Spyre Therapeutics (FRA:3920) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:3920 Spyre Therapeutics Inc FRA:3920
33 GF Score
Price €77.00
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics OCF Margin %?

Spyre Therapeutics FRA:3920 +0.65% 33 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, Spyre Therapeutics ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Spyre Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was €-49.63 Mil. Spyre Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Spyre Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Spyre Therapeutics's current OCF Yield % is -2.44%.

The historical rank and industry rank for Spyre Therapeutics's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Spyre Therapeutics was -286.65%. The lowest was -11276.52%. And the median was -650.46%.

FRA:3920's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Spyre Therapeutics OCF Margin % Related Terms

Spyre Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics OCF Margin % Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -286.66 -3,440.47 -11,282.88 0.00 0.00

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3920
33GF Score
Spyre Therapeutics Inc FRA:3920
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Spyre Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-144.541/0
= %

Spyre Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-49.627/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Spyre Therapeutics (FRA:3920) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 958 companies in the Biotechnology industry.
Is Spyre Therapeutics' OCF Margin % too high?
Spyre Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' OCF Margin % compare to PTGX and CELC?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 958 companies for OCF Margin %. This places Spyre Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score

Get the complete analysis for FRA:3920

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price